Details of the Drug

General Information of Drug (ID: DM35M8J)

Drug Name

Thioridazine

Synonyms

Aldazine; Mallorol; Malloryl; Meleril; Mellaril; Mellarit; Mellerets; Mellerette; Melleretten; Melleril; Melleryl; Metlaril; Novoridazine; Orsanil; Ridazine; Sonapax; Stalleril; Thioridazin; Thioridazinum; Thioxidazine; Tioridazin; Tioridazina; Thioridazine Hcl; Thioridazine Hcl Intensol; Thioridazine prolongatum; Thoridazine hydrochloride; Dl-Thioridazine; Mellaril (TN); Mellaril-S; Melleril (liquid); Novoridazine (TN); TP-21; Thioridazine, prolongatum; Thioridazinum [INN-Latin]; Thioril (TN); Tioridazina [INN-Spanish]; Mellaril-S (TN); Thioridazine (USP/INN); Thioridazine [USAN:INN:BAN]; Mellaril (*Hydrochloride*); (+-)-Thioridazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylthio)phenothiazine; 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylthio)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine; 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine; 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antipsychotic Agents

Affected Organisms

Humans and other mammals

ATC Code

N05AC02: Thioridazine

N05AC: Phenothiazines with piperidine structure

N05A: ANTIPSYCHOTICS

N05: PSYCHOLEPTICS

N: NERVOUS SYSTEM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

370.6

Logarithm of the Partition Coefficient (xlogp)

5.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The absorption of drug is 60% []
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 21 - 25 hours [3]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 35.88942 micromolar/kg/day [4]
Water Solubility: The ability of drug to dissolve in water is measured as 1 mg/mL [2]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Seizures (incl subtypes)	Not Available	KCNJ3	OTHQG16J	[5]
Tardive dyskinesia	Not Available	DRD2	OTBLXKEG	[5]
Tardive dyskinesia	Not Available	DRD3	OT0OFFKB	[5]
Tardive dyskinesia	Not Available	DRD4	OTAJTO7N	[5]
-----------

Chemical Identifiers

Formula: C21H26N2S2
IUPAC Name: 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine
Canonical SMILES: CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC
InChI: InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
InChIKey: KLBQZWRITKRQQV-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5452
ChEBI ID: CHEBI:9566
CAS Number: 50-52-2
UNII: N3D6TG58NI
DrugBank ID: DB00679
TTD ID: D0U1OE
VARIDT ID: DR00785
INTEDE ID: DR1581
ACDINA ID: D00672

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[6]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[8]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acid ceramidase (ASAH1)	OT1DNGXL	ASAH1_HUMAN	Gene/Protein Processing	[10]
Alpha-1-antichymotrypsin (SERPINA3)	OT9BP2S0	AACT_HUMAN	Gene/Protein Processing	[11]
AP-1 complex subunit sigma-1A (AP1S1)	OTQ2H8DN	AP1S1_HUMAN	Gene/Protein Processing	[11]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Gene/Protein Processing	[10]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[12]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Gene/Protein Processing	[13]
Corticoliberin (CRH)	OT2MOC4T	CRF_HUMAN	Gene/Protein Processing	[14]
Cyclin-dependent kinase 4 (CDK4)	OT7EP05T	CDK4_HUMAN	Gene/Protein Processing	[12]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Gene/Protein Processing	[12]
Cyclin-dependent kinase inhibitor 2A (CDKN2A)	OTN0ZWAE	CDN2A_HUMAN	Gene/Protein Processing	[12]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Schizophrenia

ICD Disease Classification

6A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
P-glycoprotein 1 (ABCB1)	DTP	P-GP	9.39E-02	1.07E-01	2.80E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	2.40E-01	-3.31E-02	-1.97E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Thioridazine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Quetiapine	DM1N62C	Major	Additive CNS depression effects by the combination of Thioridazine and Quetiapine.	Schizophrenia [6A20]	[15]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Mesoridazine.	Schizophrenia [6A20]	[16]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Aripiprazole.	Schizophrenia [6A20]	[17]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Iloperidone.	Schizophrenia [6A20]	[18]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Paliperidone.	Schizophrenia [6A20]	[18]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Molindone.	Schizophrenia [6A20]	[17]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Thiothixene.	Schizophrenia [6A20]	[17]
Trifluoperazine	DMKBYWI	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Trifluoperazine.	Schizophrenia [6A20]	[19]
Risperidone	DMN6DXL	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Risperidone.	Schizophrenia [6A20]	[18]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Amisulpride.	Schizophrenia [6A20]	[18]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Asenapine.	Schizophrenia [6A20]	[18]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Pimozide.	Schizophrenia [6A20]	[18]
-----------


⏷ Show the Full List of 12 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Thioridazine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[20]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Midostaurin.	Acute myeloid leukaemia [2A60]	[18]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Idarubicin.	Acute myeloid leukaemia [2A60]	[18]
Daunorubicin	DMQUSBT	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Daunorubicin.	Acute myeloid leukaemia [2A60]	[18]
Arn-509	DMT81LZ	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Arn-509.	Acute myeloid leukaemia [2A60]	[20]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Oliceridine.	Acute pain [MG31]	[20]
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Scopolamine.	Addictive disorder [6C50-6C5Z]	[17]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[21]
Tripelennamine	DMZBU15	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[21]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Memantine.	Alzheimer disease [8A20]	[17]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Thioridazine when combined with Rivastigmine.	Alzheimer disease [8A20]	[22]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Thioridazine and Metronidazole.	Amoebiasis [1A36]	[16]
Isosorbide dinitrate	DMBI4JG	Moderate	Additive hypotensive effects by the combination of Thioridazine and Isosorbide dinitrate.	Anal fissure/fistula [DB50]	[23]
Trimethaphan	DMHF4IQ	Moderate	Additive hypotensive effects by the combination of Thioridazine and Trimethaphan.	Aneurysm/dissection [BD50]	[24]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Ivabradine.	Angina pectoris [BA40]	[20]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Bepridil.	Angina pectoris [BA40]	[20]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Thioridazine and Amyl nitrite.	Angina pectoris [BA40]	[23]
Nifedipine	DMSVOZT	Moderate	Additive hypotensive effects by the combination of Thioridazine and Nifedipine.	Angina pectoris [BA40]	[23]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[18]
Cilostazol	DMZMSCT	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Cilostazol.	Arterial occlusive disease [BD40]	[18]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Posaconazole.	Aspergillosis [1F20]	[18]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Thioridazine and Levalbuterol.	Asthma [CA23]	[25]
Terbutaline	DMD4381	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Terbutaline.	Asthma [CA23]	[26]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Pirbuterol.	Asthma [CA23]	[25]
Ephedrine	DMMV0KW	Moderate	Antagonize the effect of Thioridazine when combined with Ephedrine.	Asthma [CA23]	[27]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Salbutamol.	Asthma [CA23]	[28]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Formoterol.	Asthma [CA23]	[26]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[18]
Desipramine	DMT2FDC	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[19]
Ofloxacin	DM0VQN3	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Clarithromycin	DM4M1SG	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[18]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Thioridazine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[18]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Gemifloxacin	DMHT34O	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Norfloxacin	DMIZ6W2	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Levofloxacin	DMS60RB	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Lomefloxacin	DMVRH9C	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Telithromycin	DMZ4P3A	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Telithromycin.	Bacterial infection [1A00-1C4Z]	[20]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Retigabine.	Behcet disease [4A62]	[20]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Cariprazine.	Bipolar disorder [6A60]	[17]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Thioridazine and Loperamide.	Bowel habit change [ME05]	[29]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Eribulin.	Breast cancer [2C60-2C6Y]	[18]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Bosutinib.	Breast cancer [2C60-2C6Y]	[18]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Thioridazine when combined with Acetylcholine.	Cataract [9B10]	[30]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Thioridazine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[20]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[31]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[26]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[25]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Thioridazine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[26]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[31]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Thioridazine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[26]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[26]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Thioridazine and Dihydrocodeine.	Chronic pain [MG30]	[32]
Isoproterenol	DMK7MEY	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Isoproterenol.	Conduction disorder [BC63]	[26]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Thioridazine and Olopatadine.	Conjunctiva disorder [9A60]	[33]
Halothane	DM80OZ5	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Halothane.	Corneal disease [9A76-9A78]	[18]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Thioridazine and Propofol.	Corneal disease [9A76-9A78]	[34]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Sevoflurane.	Corneal disease [9A76-9A78]	[18]
Alfentanil	DMVO0UB	Major	Additive CNS depression effects by the combination of Thioridazine and Alfentanil.	Corneal disease [9A76-9A78]	[35]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Thioridazine and Remifentanil.	Corneal disease [9A76-9A78]	[35]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Probucol.	Coronary atherosclerosis [BA80]	[20]
Clofazimine	DMEBOFW	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Clofazimine.	Crohn disease [DD70]	[20]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Mifepristone.	Cushing syndrome [5A70]	[18]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Pasireotide.	Cushing syndrome [5A70]	[18]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Osilodrostat.	Cushing syndrome [5A70]	[20]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Thioridazine and Cyclandelate.	Dementia [6D80-6D8Z]	[24]
Sertraline	DM0FB1J	Major	Decreased metabolism of Thioridazine caused by Sertraline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[36]
Trimipramine	DM1SC8M	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Trimipramine.	Depression [6A70-6A7Z]	[19]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[17]
Paroxetine	DM5PVQE	Major	Decreased metabolism of Thioridazine caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[36]
Selegiline	DM6034S	Moderate	Additive CNS depression effects by the combination of Thioridazine and Selegiline.	Depression [6A70-6A7Z]	[37]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Thioridazine and Isocarboxazid.	Depression [6A70-6A7Z]	[37]
Escitalopram	DMFK9HG	Major	Decreased metabolism of Thioridazine caused by Escitalopram mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[36]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Thioridazine and Tranylcypromine.	Depression [6A70-6A7Z]	[38]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Thioridazine and OPC-34712.	Depression [6A70-6A7Z]	[17]
Phenelzine	DMHIDUE	Moderate	Additive CNS depression effects by the combination of Thioridazine and Phenelzine.	Depression [6A70-6A7Z]	[37]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Clomipramine.	Depression [6A70-6A7Z]	[19]
Doxepin	DMPI98T	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Doxepin.	Depression [6A70-6A7Z]	[19]
Maprotiline	DMPWB7T	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Maprotiline.	Depression [6A70-6A7Z]	[18]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Thioridazine and Esketamine.	Depression [6A70-6A7Z]	[16]
Nitroglycerin	DMQ2491	Moderate	Additive hypotensive effects by the combination of Thioridazine and Nitroglycerin.	Diabetic foot ulcer [BD54]	[23]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Mepenzolate.	Digestive system disease [DE2Z]	[21]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Oxybutynine.	Discovery agent [N.A.]	[17]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[18]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Meclizine.	Dizziness and giddiness [MB48]	[17]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Deutetrabenazine.	Dystonic disorder [8A02]	[18]
Zonisamide	DM0DTF7	Major	Additive CNS depression effects by the combination of Thioridazine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[39]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Thioridazine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Thioridazine and Phenoxybenzamine.	Essential hypertension [BA00]	[23]
Nadolol	DMW6GVL	Moderate	Additive hypotensive effects by the combination of Thioridazine and Nadolol.	Essential hypertension [BA00]	[23]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Solifenacin.	Functional bladder disorder [GC50]	[18]
Mirabegron	DMS1GYT	Major	Decreased metabolism of Thioridazine caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[36]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Tolterodine.	Functional bladder disorder [GC50]	[17]
Pentamidine	DMHZJCG	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Pentamidine.	Fungal infection [1F29-1F2F]	[18]
Terbinafine	DMI6HUW	Major	Decreased metabolism of Thioridazine caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[36]
Ketoconazole	DMPZI3Q	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Ketoconazole.	Fungal infection [1F29-1F2F]	[18]
Amphotericin B	DMTAJQE	Moderate	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Amphotericin B.	Fungal infection [1F29-1F2F]	[16]
Phentolamine	DMXYJOB	Moderate	Additive hypotensive effects by the combination of Thioridazine and Phentolamine.	Gangrene [MC85]	[23]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Propantheline.	Gastric ulcer [DA60]	[17]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[18]
Acetazolamide	DM1AF5U	Moderate	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Acetazolamide.	Glaucoma [9C61]	[16]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Thioridazine when combined with Pilocarpine.	Glaucoma [9C61]	[30]
Eplerenone	DMF0NQR	Moderate	Additive hypotensive effects by the combination of Thioridazine and Eplerenone.	Heart failure [BD10-BD1Z]	[23]
Chlorothiazide	DMLHESP	Moderate	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Chlorothiazide.	Heart failure [BD10-BD1Z]	[16]
Furosemide	DMMQ8ZG	Moderate	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Furosemide.	Heart failure [BD10-BD1Z]	[16]
Bumetanide	DMRV7H0	Moderate	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Bumetanide.	Heart failure [BD10-BD1Z]	[16]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[16]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Thioridazine and Procarbazine.	Hodgkin lymphoma [2B30]	[37]
MK-1439	DM215WE	Major	Increased metabolism of Thioridazine caused by MK-1439 mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Delavirdine	DM3NF5G	Major	Decreased metabolism of Thioridazine caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[41]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Thioridazine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Thioridazine and Isosorbide mononitrate.	Hydrocephalus [8D64]	[23]
Cinacalcet	DMCX0K3	Major	Decreased metabolism of Thioridazine caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[36]
Eprosartan	DM07K2I	Moderate	Additive hypotensive effects by the combination of Thioridazine and Eprosartan.	Hypertension [BA00-BA04]	[23]
Acebutolol	DM0TI4U	Moderate	Additive hypotensive effects by the combination of Thioridazine and Acebutolol.	Hypertension [BA00-BA04]	[23]
Moexipril	DM26E4B	Moderate	Additive hypotensive effects by the combination of Thioridazine and Moexipril.	Hypertension [BA00-BA04]	[23]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Thioridazine and Captopril.	Hypertension [BA00-BA04]	[23]
Penbutolol	DM4ES8F	Moderate	Additive hypotensive effects by the combination of Thioridazine and Penbutolol.	Hypertension [BA00-BA04]	[24]
Methyldopa	DM5I621	Moderate	Additive hypotensive effects by the combination of Thioridazine and Methyldopa.	Hypertension [BA00-BA04]	[23]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Thioridazine and Nebivolol.	Hypertension [BA00-BA04]	[23]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Thioridazine and Levamlodipine.	Hypertension [BA00-BA04]	[23]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Thioridazine and TAK-491.	Hypertension [BA00-BA04]	[23]
Fenoldopam	DMFAOKP	Moderate	Additive hypotensive effects by the combination of Thioridazine and Fenoldopam.	Hypertension [BA00-BA04]	[23]
Indapamide	DMGN1PW	Moderate	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Indapamide.	Hypertension [BA00-BA04]	[16]
Trichlormethiazide	DMHAQCO	Moderate	Additive hypotensive effects by the combination of Thioridazine and Trichlormethiazide.	Hypertension [BA00-BA04]	[24]
Diazoxide	DML1538	Moderate	Additive hypotensive effects by the combination of Thioridazine and Diazoxide.	Hypertension [BA00-BA04]	[23]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Thioridazine and Perindopril.	Hypertension [BA00-BA04]	[23]
Felodipine	DMOSW35	Moderate	Additive hypotensive effects by the combination of Thioridazine and Felodipine.	Hypertension [BA00-BA04]	[23]
Deserpidine	DMRH7CV	Moderate	Additive hypotensive effects by the combination of Thioridazine and Deserpidine.	Hypertension [BA00-BA04]	[23]
Telmisartan	DMS3GX2	Moderate	Additive hypotensive effects by the combination of Thioridazine and Telmisartan.	Hypertension [BA00-BA04]	[23]
Irbesartan	DMTP1DC	Moderate	Additive hypotensive effects by the combination of Thioridazine and Irbesartan.	Hypertension [BA00-BA04]	[23]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Thioridazine and Hydralazine.	Hypertension [BA00-BA04]	[23]
Lisinopril	DMUOK4C	Moderate	Additive hypotensive effects by the combination of Thioridazine and Lisinopril.	Hypertension [BA00-BA04]	[23]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Thioridazine and Clevidipine butyrate.	Hypertension [BA00-BA04]	[23]
Fludrocortisone	DMUDIR8	Moderate	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Fludrocortisone.	Hypo-osmolality/hyponatraemia [5C72]	[16]
Givosiran	DM5PFIJ	Major	Decreased metabolism of Thioridazine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[41]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[17]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Amantadine.	Influenza [1E30-1E32]	[42]
Berotralstat	DMWA2DZ	Major	Decreased metabolism of Thioridazine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[43]
Propiomazine	DMKY8V1	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Propiomazine.	Insomnia [7A00-7A0Z]	[44]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Thioridazine and ITI-007.	Insomnia [7A00-7A0Z]	[17]
Polyethylene glycol	DM4I1JP	Major	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[45]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Phenolphthalein.	Irritable bowel syndrome [DD91]	[16]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Clidinium.	Irritable bowel syndrome [DD91]	[17]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Dicyclomine.	Irritable bowel syndrome [DD91]	[17]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Thioridazine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[22]
Glycerol phenylbutyrate	DMDGRQO	Major	Decreased metabolism of Thioridazine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[36]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Crizotinib.	Lung cancer [2C25]	[18]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Thioridazine and Porfimer Sodium.	Lung cancer [2C25]	[46]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Ceritinib.	Lung cancer [2C25]	[18]
Dacomitinib	DMOH8VY	Major	Decreased metabolism of Thioridazine caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[41]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Halofantrine.	Malaria [1F40-1F45]	[16]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Hydroxychloroquine.	Malaria [1F40-1F45]	[18]
Primaquine	DMWQ16I	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Primaquine.	Malaria [1F40-1F45]	[18]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[18]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[18]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Vemurafenib.	Melanoma [2C30]	[18]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Thioridazine and LGX818.	Melanoma [2C30]	[18]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Thioridazine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[47]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Thioridazine and Lasmiditan.	Migraine [8A80]	[48]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Thioridazine and Flibanserin.	Mood disorder [6A60-6E23]	[49]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Panobinostat.	Multiple myeloma [2A83]	[18]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Thioridazine and Thalidomide.	Multiple myeloma [2A83]	[20]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Siponimod.	Multiple sclerosis [8A40]	[16]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Fingolimod.	Multiple sclerosis [8A40]	[18]
Ozanimod	DMT6AM2	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Ozanimod.	Multiple sclerosis [8A40]	[18]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Romidepsin.	Mycosis fungoides [2B01]	[18]
Fedratinib	DM4ZBK6	Major	Decreased metabolism of Thioridazine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[36]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[18]
Dextroamphetamine	DMMIHVP	Moderate	Antagonize the effect of Thioridazine when combined with Dextroamphetamine.	Narcolepsy [7A20]	[27]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Phenindamine.	Nasopharyngitis [CA00]	[21]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Dimenhydrinate.	Nausea/vomiting [MD90]	[17]
Promethazine	DM6I5GR	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Promethazine.	Nausea/vomiting [MD90]	[19]
Rolapitant	DM8XP26	Major	Decreased metabolism of Thioridazine caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[36]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Cyclizine.	Nausea/vomiting [MD90]	[17]
Metoclopramide	DMFA5MY	Major	Additive antidopaminergic effects by the combination of Thioridazine and Metoclopramide.	Nausea/vomiting [MD90]	[50]
Granisetron	DMIUW25	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Granisetron.	Nausea/vomiting [MD90]	[18]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Dolasetron.	Nausea/vomiting [MD90]	[18]
Ondansetron	DMOTQ1I	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Ondansetron.	Nausea/vomiting [MD90]	[18]
Bupropion	DM5PCS7	Major	Decreased metabolism of Thioridazine caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[36]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Entrectinib.	Non-small cell lung cancer [2C25]	[20]
Phendimetrazine	DM6TS1N	Moderate	Antagonize the effect of Thioridazine when combined with Phendimetrazine.	Obesity [5B80-5B81]	[27]
Amfepramone	DM9YSNQ	Moderate	Antagonize the effect of Thioridazine when combined with Amfepramone.	Obesity [5B80-5B81]	[27]
Lorcaserin	DMG6OYJ	Major	Decreased metabolism of Thioridazine caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[36]
Benzphetamine	DMIJATC	Moderate	Antagonize the effect of Thioridazine when combined with Benzphetamine.	Obesity [5B80-5B81]	[27]
Dexfenfluramine	DMJ7YDS	Major	Decreased metabolism of Thioridazine caused by Dexfenfluramine mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[43]
Polythiazide	DMCH80F	Moderate	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Polythiazide.	Oedema [MG29]	[16]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[20]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Thioridazine and Apraclonidine.	Optic nerve disorder [9C40]	[51]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Rucaparib.	Ovarian cancer [2C73]	[18]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Thioridazine and Oxymorphone.	Pain [MG30-MG3Z]	[35]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Thioridazine and Dezocine.	Pain [MG30-MG3Z]	[32]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Flavoxate.	Pain [MG30-MG3Z]	[17]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Thioridazine and Nalbuphine.	Pain [MG30-MG3Z]	[35]
Buprenorphine	DMPRI8G	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Buprenorphine.	Pain [MG30-MG3Z]	[18]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Thioridazine and Hydrocodone.	Pain [MG30-MG3Z]	[35]
Safinamide	DM0YWJC	Moderate	Additive CNS depression effects by the combination of Thioridazine and Safinamide.	Parkinsonism [8A00]	[37]
Pergolide	DM14MAE	Moderate	Antagonize the effect of Thioridazine when combined with Pergolide.	Parkinsonism [8A00]	[52]
Opicapone	DM1BKA6	Moderate	Additive hypotensive effects by the combination of Thioridazine and Opicapone.	Parkinsonism [8A00]	[53]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Thioridazine and Rasagiline.	Parkinsonism [8A00]	[37]
Biperiden	DME78OA	Moderate	Antagonize the effect of Thioridazine when combined with Biperiden.	Parkinsonism [8A00]	[54]
Levodopa	DMN3E57	Moderate	Antagonize the effect of Thioridazine when combined with Levodopa.	Parkinsonism [8A00]	[52]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Pimavanserin.	Parkinsonism [8A00]	[18]
Bromocriptine	DMVE3TK	Moderate	Antagonize the effect of Thioridazine when combined with Bromocriptine.	Parkinsonism [8A00]	[52]
Apomorphine	DMX38HQ	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Apomorphine.	Parkinsonism [8A00]	[18]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[55]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Lefamulin.	Pneumonia [CA40]	[20]
Hydrocortisone	DMGEMB7	Moderate	Increased risk of ventricular arrhythmias by the combination of Thioridazine and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[16]
Ritodrine	DM4V6RL	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Ritodrine.	Preterm labour/delivery [JB00]	[26]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Degarelix.	Prostate cancer [2C82]	[18]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Enzalutamide.	Prostate cancer [2C82]	[18]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Relugolix.	Prostate cancer [2C82]	[18]
Bicalutamide	DMZMSPF	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Bicalutamide.	Prostate cancer [2C82]	[18]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Thioridazine and Terazosin.	Prostate hyperplasia [GA90]	[23]
Tamsulosin	DM5QF9V	Moderate	Additive hypotensive effects by the combination of Thioridazine and Tamsulosin.	Prostate hyperplasia [GA90]	[23]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Thioridazine and Silodosin.	Prostate hyperplasia [GA90]	[23]
Levomepromazine	DMIKFEL	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[44]
Tolazoline	DMI40NL	Moderate	Additive hypotensive effects by the combination of Thioridazine and Tolazoline.	Pulmonary hypertension [BB01]	[24]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[20]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Thioridazine when combined with Neupro.	Restless legs syndrome [7A80]	[52]
Oxamniquine	DM2QDX1	Major	Decreased metabolism of Thioridazine caused by Oxamniquine mediated inhibition of CYP450 enzyme.	Schistosomiasis [1F86]	[43]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Thioridazine and Fentanyl.	Sensation disturbance [MB40]	[35]
Sufentanil	DMU7YEL	Major	Additive CNS depression effects by the combination of Thioridazine and Sufentanil.	Sensation disturbance [MB40]	[35]
Vardenafil	DMTBGW8	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[18]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Thioridazine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[18]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[18]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[18]
Doxorubicin	DMVP5YE	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[18]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Pitolisant.	Somnolence [MG42]	[18]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[18]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Lenvatinib.	Thyroid cancer [2D10]	[18]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Cabozantinib.	Thyroid cancer [2D10]	[18]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Papaverine.	Tonus and reflex abnormality [MB47]	[56]
Tizanidine	DMR2IQ4	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Tizanidine.	Tonus and reflex abnormality [MB47]	[18]
Tacrolimus	DMZ7XNQ	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Tacrolimus.	Transplant rejection [NE84]	[18]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[17]
Methdilazine	DMAUHQX	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[44]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[17]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[44]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[17]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[21]
Azatadine	DMZ80SB	Moderate	Additive anticholinergic effects by the combination of Thioridazine and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[21]
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[18]
Flecainide	DMSQDLE	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[18]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Thioridazine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[18]
-----------


⏷ Show the Full List of 248 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Carmellose sodium	E00625	Not Available	Disintegrant
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose	E00634	Not Available	Coating agent
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Thioridazine 10 mg tablet	10 mg	Oral Tablet	Oral
Thioridazine 100 mg tablet	100 mg	Oral Tablet	Oral
Thioridazine 25 mg tablet	25 mg	Oral Tablet	Oral
Thioridazine 50 mg tablet	50 mg	Oral Tablet	Oral
Thioridazine Hydrochloride 25mg tablet	25mg	Tablet	Oral
Thioridazine Hydrochloride 100mg tablet	100mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 100).
2	BDDCS applied to over 900 drugs
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
6	Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4.
7	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
8	Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003 May;59(1):45-50.
9	CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems. Antimicrob Agents Chemother. 2013 Nov;57(11):5448-56.
10	Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
11	A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
12	A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol. 2011 Jan;120(1):121-7. doi: 10.1016/j.ygyno.2010.10.003. Epub 2010 Oct 29.
13	Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
14	Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases. Neuropsychopharmacology. 2006 Apr;31(4):853-65. doi: 10.1038/sj.npp.1300911.
15	Johnson AL, Hollister LE, Berger PA "The anticholinergic intoxication syndrome: diagnosis and treatment." J Clin Psychiatry 42 (1981): 313-7. [PMID: 7251568]
16	Cerner Multum, Inc. "Australian Product Information.".
17	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
18	Canadian Pharmacists Association.
19	Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993): 89-95. [PMID: 8422746]
20	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
22	Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
23	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
24	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
25	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
26	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
27	Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
28	Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
29	Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
30	Multum Information Services, Inc. Expert Review Panel.
31	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
32	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
33	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
34	Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
35	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
36	Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
37	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
38	Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62. [PMID: 14197995]
39	Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
40	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
41	Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JAG, Berecz R, Duran M, Benitez J "Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients." J Clin Psychopharmacol 19 (1999): 494-9. [PMID: 10587283]
42	Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
43	Fletcher GF, Kazamias TM "Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias." Am Heart J 78 (1969): 135-8. [PMID: 5794785]
44	El-Yousef MK, Manier DH "Tricyclic antidepressants and phenothiazines." JAMA 229 (1974): 1419. [PMID: 4152942]
45	Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
46	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
47	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
48	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
49	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
50	Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
51	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
52	Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
53	Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.
54	Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967): 1112-3. [PMID: 6021058]
55	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
56	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]